Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the deadliest malignancies worldwide due to the lack of effective treatments. Chemoprevention in high-risk patients is a promising, alternative strategy. In this study, pioglitazone was investigated for its ability to prevent hepatocarcinogenesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shen, Ghoshal, Sarani, Sojoodi, Mozhdeh, Arora, Gunisha, Masia, Ricard, Erstad, Derek J., Lanuti, Michael, Hoshida, Yujin, Baumert, Thomas F., Tanabe, Kenneth K., Fuchs, Bryan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
2018 SSAT Plenary Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328630/
https://www.ncbi.nlm.nih.gov/pubmed/30367397
http://dx.doi.org/10.1007/s11605-018-4004-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328630/
https://www.ncbi.nlm.nih.gov/pubmed/30367397
http://dx.doi.org/10.1007/s11605-018-4004-6

Ejemplares similares